一、董事会会议召开情况 北京天智航医疗科技股份有限公司（以下简称"公司"）第六届董事会第二 十二次会议通知于 2025 年 8 月 19 日以电子邮件方式送达公司全体董事，于 2025 年 8 月 27 日以现场结合通讯方式召开。本次会议应出席董事 9 人，实际出席董 事 9 人，会议由董事长张送根先生主持。本次会议的召集、召开和表决程序符合 《中华人民共和国公司法》《公司章程》的有关规定，会议决议合法有效。 二、董事会会议审议情况 经与会董事表决，形成如下决议： 具体内容详见公司同日刊登在上海证券交易所网站（www.sse.com.cn）的《公 司 2025 年半年度报告》及《公司 2025 年半年度报告摘要》。 表决结果：同意 9 票，反对 0 票，弃权 0 票；通过。 证券代码：688277 证券简称：天智航 公告编号：2025-030 北京天智航医疗科技股份有限公司 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 本议案已经公司董事会审计委员会审议通过。 告>的议案》 报告期，公司严格按照《募集资金管理办法》及《募 ...

证券代码：688277 证券简称：天智航 公告编号：2025-031 北京天智航医疗科技股份有限公司 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、监事会会议召开情况 北京天智航医疗科技股份有限公司（以下简称"公司"）第五届监事会第十 次会议通知于 2025 年 8 月 19 日以电子邮件方式送达公司全体监事，于 2025 年 次会议由监事会主席张维军先生主持。本次监事会会议的召开符合《公司法》 《公 司章程》等有关规定，会议决议合法有效。 二、监事会会议审议情况 全体监事以投票方式通过如下决议： 公司 2025 年半年度报告的编制和审议程序符合相关法律法规及《公司章程》 等相关规定；公司 2025 年半年度报告的内容和格式符合相关规定，公允地反映 了公司 2025 年半年度的财务状况和经营成果；2025 年半年度报告编制过程中， 未发现公司参与报告编制和审议的人员有违反保密规定的行为；监事会全体成员 保证公司 2025 年半年度报告披露的信息真实、准确、完整，不存在任何虚假记 载、误导性陈述或重大遗漏，并对其内容的 ...

人民财讯8月27日电，天智航(688277)8月27日晚间披露半年报，2025年上半年，公司实现营业收入1.25 亿元，同比增长114.89%；归属于上市公司股东的净利润-5754.82万元；基本每股收益-0.13元。 ...

Core Viewpoint - Beijing Tinavi Medical Technologies Co., Ltd. reported significant growth in revenue and operational metrics for the first half of 2025, indicating a strong market position in the orthopedic surgical robot industry. Company Overview and Financial Indicators - The company achieved a revenue of approximately 125.31 million yuan, representing a year-on-year increase of 114.89% [2][6] - The net profit attributable to shareholders was approximately -57.55 million yuan, with a decrease in losses of 27.96% compared to the previous year [2][6] - The total assets of the company increased by 5.35% to approximately 1.78 billion yuan [2][6] Business Model and Product Offerings - The company focuses on the development and production of orthopedic surgical robots, with its core product being the "Tianji" series of surgical robots [5][12] - The company employs a hybrid sales model combining direct sales and distribution, providing training and clinical support to medical institutions [7][12] - The company has established a comprehensive R&D system and collaborates with universities and hospitals to enhance its product offerings [14][12] Industry Context - The orthopedic surgical robot industry is experiencing rapid growth, driven by technological advancements and increasing demand for minimally invasive surgeries [8][10] - The company holds a leading market share in China, with its products being used in over 200 medical institutions and completing more than 120,000 surgeries [10][12] - The industry is characterized by high technical barriers, requiring significant R&D investment and collaboration across multiple disciplines [9][10] Innovation and R&D - The company has developed several innovative products, including the Tianji SIRUI orthopedic surgical robot, which enhances surgical precision and efficiency [13][12] - The company has a strong focus on integrating advanced technologies such as AI and multi-modal imaging into its surgical robots [17][18] - The company has filed for 412 patents, establishing a robust technological barrier in the orthopedic surgical robot field [14][12]

第一节 重要提示 规划，投资者应当到上海证券交易所网站（www.sse.com.cn）网站仔细阅读半年度报告全文。 公司已在半年度报告中详细阐述公司在经营过程中可能面临的各种风险及应对措施，敬请查阅半 年度报告第三节"管理层讨论与分析"。 完整性，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 无 □适用 √不适用 第二节 公司基本情况 公司股票简况 公司股票简况 股票种类 股票上市交易所 股票简称 股票代码 变更前股票简称 人民币普通股（A股） 上海证券交易所科创板 天智航 688277 不适用 公司存托凭证简况 □适用 √不适用 联系人和联系方式 联系人和联系方式 董事会秘书（信息披露境内代表） 证券事务代表 姓名 黄军辉 孙晓燕 电话 010-82156660-8009 010-82156660-8009 办公地址 北京市海淀区建枫路（南延）中关村 北京市海淀区建枫路（南延）中关村 西三旗金隅科技园8号院2号楼 西三旗金隅科技园8号院2号楼 北京天智航医疗科技股份有限公司2025 年半年度报告摘要 电子信箱 tinavi@tinavi.com tinavi@tinavi.com 单位 ...

北京天智航医疗科技股份有限公司 关于 2023 年限制性股票激励计划首次及预留授予部分 北京天智航医疗科技股份有限公司（以下简称"公司"）监事会依据《中华人 民共和国公司法》（以下简称"《公司法》"）、《中华人民共和国证券法》（以 下简称"《证券法》"）、《上市公司股权激励管理办法》（以下简称"《管理 办法》"）、《上海证券交易所科创板股票上市规则》（以下简称"《上市规则》"） 和《北京天智航医疗科技股份有限公司章程》（以下简称"《公司章程》"）等有 关规定，对本次限制性股票激励计划首次及预留授予部分第二个归属期符合归属 条件的激励对象名单进行审核，发表核查意见如下： 经核查，除 11 名激励对象（首次授予 5 名，预留授予 9 名，首次和预留人 员存在重合）离职外，本激励计划首次及预留授予拟归属的 148 名激励对象（首 次授予 95 名，预留授予 117 名，首次和预留人员存在重合）绩效考核结果合规、 真实，不存在虚假、故意隐瞒等相关情况，符合《公司法》《证券法》等法律、 法规和规范性文件以及《公司章程》规定的任职资格，符合《管理办法》《上市 规则》等法律、法规和规范性文件规定的激励对象条件，符合《公司 ...

证券代码：688277 证券简称：天智航 公告编号：2025-035 北京天智航医疗科技股份有限公司 关于增加 2025 年度日常关联交易预计额度的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ? 是否需要提交股东大会审议：是 ? 日常关联交易对公司的影响：本次增加 2025 年度日常关联交易预计额度 事项属于公司日常关联交易，是以公司正常生产经营业务为基础，以市场价格为 定价依据，不影响公司的独立性，不存在损害公司及股东利益的情形，不会对关 联人形成较大的依赖。 一、增加日常关联交易基本情况 （一）增加日常关联交易履行的审议程序 召开第六届董事会独立董事专门会议第六次会议审议通过了《关于增加 2025 年 度日常关联交易预计额度的议案》，该议案获得全体独立董事一致同意，并同意 将该议案提交公司董事会审议。 会第十次会议，分别审议通过了《关于增加 2025 年度日常关联交易预计额度的 议案》，本次增加 2025 年度日常关联交易预计额度为 3,000.00 万元，关联董事 张送根、王彬彬进行了回避表 ...

Core Viewpoint - The report outlines Beijing Tianzhihang Medical Technology Co., Ltd.'s progress and effectiveness in implementing its "Quality Improvement and Efficiency Enhancement" action plan for 2025, emphasizing its commitment to high-quality development and innovation in the orthopedic surgery robot industry. Group 1: Business Performance - The company achieved a revenue of 125.31 million yuan, representing a year-on-year growth of 114.89% [2] - The Tianji orthopedic surgical robot performed over 22,000 surgeries from January to June 2025, with a cumulative total exceeding 120,000 surgeries by the end of the reporting period [2] - The company is focused on enhancing product performance and expanding its product range, covering various orthopedic surgical procedures [2] Group 2: Research and Innovation - The company has applied for a total of 619 patents, including 245 invention patents, and has been granted 428 patents, with 412 currently valid [3] - Two innovative products, Tianji SIRUI orthopedic surgical robot and Tianxuan Xingyao 3D C-arm, received approval for market launch, enhancing surgical efficiency and safety [3] Group 3: Corporate Governance - The company has established a robust governance structure, ensuring clear responsibilities and effective checks and balances [4] - Training programs have been implemented to enhance compliance awareness among major stakeholders [4] Group 4: Talent Development - The company emphasizes talent development through comprehensive training programs tailored to various employee needs [5] - Long-term incentive mechanisms have been established to attract and retain top talent, aligning interests among shareholders, the company, and core team members [5] Group 5: Information Disclosure - The company prioritizes information disclosure to enhance governance and market transparency, adhering to relevant regulations [6] - Various initiatives have been undertaken to communicate with investors, including performance briefings and investor engagement activities [6]

Core Viewpoint - The report confirms that the second vesting period of the 2023 restricted stock incentive plan for Beijing Tianzhihang Medical Technology Co., Ltd. has met the vesting conditions, allowing for the allocation of shares to eligible participants [6][10][16]. Summary by Sections Definitions - The report defines key terms related to the incentive plan, including "restricted stock," "incentive objects," and "vesting conditions," which are essential for understanding the plan's framework [1][2]. Approval Process - The 2023 restricted stock incentive plan has undergone necessary approval procedures, including resolutions from the board of directors and the supervisory board, confirming the plan's compliance with relevant regulations [4][6]. Vesting Conditions Achievement - The board of directors has reviewed and confirmed that the vesting conditions for the second vesting period have been met, allowing for the allocation of 3.86466 million shares to 148 eligible participants [6][10]. Performance Requirements - The performance requirements for the incentive plan include achieving a revenue growth rate of at least 40% for the first vesting period and 90% for the second vesting period, or obtaining medical device registration for at least two new orthopedic surgical robots [10][11]. Allocation Details - For the first grant, 95 participants are eligible to receive 3.135355 million shares, while for the reserved grant, 117 participants are eligible for 729305 shares, both at a grant price of 8.66 yuan per share [12][14][15]. Independent Financial Advisor's Opinion - The independent financial advisor concludes that the vesting conditions have been met and that the plan complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [16].

Core Viewpoint - The legal opinion from Beijing Deheng Law Firm confirms that the second vesting period of the 2023 restricted stock incentive plan for Beijing Tianzhihang Medical Technology Co., Ltd. meets the vesting conditions and outlines the circumstances under which certain restricted stocks will be canceled [2][5][21]. Group 1: Approval and Authorization - The company has completed necessary procedures for the implementation of the 2023 restricted stock incentive plan, including approval from the board and supervisory committee [6][7]. - The independent directors have expressed that the implementation of the incentive plan is beneficial for the company's governance structure and does not harm the interests of shareholders, especially minority shareholders [7][8]. Group 2: Vesting Conditions - The second vesting period for the initial grant of restricted stocks began on May 12, 2023, and the pre-allocated grant's second vesting period will start on August 22, 2025 [10][11]. - The company has confirmed that the vesting conditions have been met, including the absence of negative audit opinions and compliance with legal regulations [11][14]. Group 3: Specifics of the Vesting - The initial grant date was May 12, 2023, with 95 individuals eligible for a total of 3.135355 million shares at a grant price of 8.66 yuan per share [20]. - The pre-allocated grant date is August 22, 2023, with 117 individuals eligible for a total of 0.729305 million shares at the same grant price [20]. Group 4: Cancellation of Restricted Stocks - A total of 172,095 restricted stocks will be canceled due to the departure of individuals who no longer meet the eligibility criteria [22]. - The cancellation aligns with the regulations set forth in the management measures and listing rules [21][22]. Group 5: Conclusion - The legal opinion concludes that both the vesting and cancellation of restricted stocks have received the necessary approvals and comply with relevant regulations [22][23].